Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
71. |
ECCT/22/08/01 | GBT Open Label inclacumab Ph3 An Open-Label Extension Study to Evaluate the Long-Term Safety of Inclacumab Administered to Participants with Sickle Cell Disease Who Have Participated in an Inclacumab Clinical Trial |
Principal Investigator(s) 1. Prof Jessie N Githanga 2. Bernhards Ragama Ogutu 3. Fredrick Asirwa Chite 4. Videlis N Nduba Site(s) in Kenya 1. Gertrude’s Children’s Hospital (Nairobi City county) 2. Strathmore University Medical Centre (Nairobi City county) 3. International Cancer Institute (ICI)-Eldoret (Uasin Gishu county) 4. KEMRI/CRDR (Nairobi City county) 5. KEMRI Siaya Clinical Research Annex (Siaya county) |
View |
72. |
ECCT/22/06/02 | Mitapivat - AG348-C-020 A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell Disease. |
Principal Investigator(s) 1. Lucas Otieno Tina 2. Bernhards Ragama Ogutu 3. Prof Jessie N Githanga 4. Videlis N Nduba 5. Janet N/A Oyieko 6. Allan Godfrey Otieno Site(s) in Kenya 1. Victoria Biomedical Research Institute (Kisumu county) 2. Strathmore University Medical Centre (Nairobi City county) 3. KEMRI/CRDR (Nairobi City county) 4. KEMRI Siaya Clinical Research Annex (Siaya county) 5. Gertrude’s Children’s Hospital (Nairobi City county) 6. KEMRI Kondele Children\'s Hospital (Kisumu county) 7. Kombewa Clinical Research Centre (Kisumu county) |
View |
73. |
ECCT/22/05/02 | BREATHER Plus A randomised open-label 2-arm, 96-week trial evaluating the efficacy, safety and acceptability of short cycle (five days on, two days off) dolutegravir/tenofovir-based triple antiretroviral therapy (ART) compared to daily dolutegravir/tenofovir-based triple ART in virologically suppressed HIV-infected adolescents aged 12 to 19 years of age in sub-Saharan Africa |
Principal Investigator(s) 1. Abraham Siika Site(s) in Kenya Moi University Clinical Research Centre |
View |
74. |
ECCT/22/05/01 | VICTORION-2 PREVENT A randomized, double-blind, placebo-controlled, multicenter trial, assessing the impact of inclisiran on major adverse cardiovascular events in participants with established cardiovascular disease |
Principal Investigator(s) 1. Anthony Gikonyo 2. ELIJAH SAMMY NYAINDA OGOLA Site(s) in Kenya 1. The Karen Hospital (Nairobi City county) 2. Centre for research in Therapeutic Sciences (CREATES (Nairobi City county) |
View |
75. |
ECCT/22/04/01 | GBT Open Label inclacumab Ph3 An Open-Label Extension Study to Evaluate the Long-Term Safety of Inclacumab Administered to Participants with Sickle Cell Disease Who Have Participated in an Inclacumab Clinical Trial |
Principal Investigator(s) 1. Bernhards Ragama Ogutu 2. Fredrick Asirwa Chite 3. Prof Jessie N Githanga 4. Videlis N Nduba Site(s) in Kenya 1. Strathmore University Medical Centre (Nairobi City county) 2. International Cancer Institute (ICI)-Eldoret (Uasin Gishu county) 3. KEMRI/CRDR (Nairobi City county) 4. KEMRI Siaya Clinical Research Annex (Siaya county) 5. Gertrude’s Children’s Hospital. (Nairobi City county) |
View |